Back to Search
Start Over
The canonical Brucella species-host dependency is changing, however, the antibiotic susceptibility profiles remain unchanged.
- Source :
-
Microbial pathogenesis [Microb Pathog] 2023 Sep; Vol. 182, pp. 106261. Date of Electronic Publication: 2023 Jul 23. - Publication Year :
- 2023
-
Abstract
- Brucellosis is a chronic disease caused by Brucella species with a wide range of hosts, from marine mammals to terrestrial species, but with strict host preferences. With the zoonotic character, the prevalence of human brucellosis cases is a reflection of animal infections. This study aimed to identify 192 Brucella isolates obtained from various sources by Bruce-ladder PCR and to determine their antibiotic susceptibilities by gradient diffusion method (E-test). As a result of the PCR, all human isolates (n = 57) were identified as B. melitensis. While 58 (82.9%) of the cattle isolates were identified as B. abortus, 59 (90.8%) of the sheep isolates were identified as B. melitensis. In addition, 12 (17.1%) of the cattle isolates and 6 (9.2%) of the sheep isolates were determined as B. melitensis and B. abortus, respectively. The primary host change behavior of B. melitensis was 1.9 times higher than that of B. abortus. While gentamicin and ciprofloxacin susceptibilities of Brucella isolates were 100%, tetracycline, doxycycline, streptomycin, trimethoprim/sulfamethoxazole and rifampicin susceptibilities were 99%, 99%, 97.4%, 91.7% and 83.9%, respectively. The lowest sensitivity of the isolates was determined against to cefoperazone as 26%. A triple-drug resistance was detected in 1 B. abortus isolate that included simultaneous resistance to cefoperazone, rifampicin, and trimethoprim/sulfamethoxazole. The high susceptibility profiles we found against to antibiotics such as tetracycline, doxycycline gentamicin and ciprofloxacin, used widely in treatment, are encouraging. However, the change in the canonical Brucella species-primary host preference suggests the need to reconsider eradication program, including updating vaccine formulations.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Subjects :
- Humans
Animals
Sheep
Cattle
Rifampin pharmacology
Doxycycline
Cefoperazone therapeutic use
Microbial Sensitivity Tests
Anti-Bacterial Agents pharmacology
Anti-Bacterial Agents therapeutic use
Tetracycline therapeutic use
Gentamicins
Trimethoprim, Sulfamethoxazole Drug Combination
Ciprofloxacin
Mammals
Brucella melitensis genetics
Brucellosis epidemiology
Brucellosis veterinary
Subjects
Details
- Language :
- English
- ISSN :
- 1096-1208
- Volume :
- 182
- Database :
- MEDLINE
- Journal :
- Microbial pathogenesis
- Publication Type :
- Academic Journal
- Accession number :
- 37488036
- Full Text :
- https://doi.org/10.1016/j.micpath.2023.106261